We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cambridge Cognition Holdings Plc | COG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 42.00 | 08:00:09 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 42.00 | 42.00 | 42.00 | 42.00 | 42.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 17/1/2025 12:01 by 40 fathoms The real significance of yesterday's RNS has only just dawned on me. Cambridge Cognition won all the cognitive measurement, data capture, and quality control work for the entire trial, even though CANTAB is only a secondary endpoint. The primary endpoint, CDR-SB, must be administered by a rater, usually a clinical psychologist.This is significant because, before the acquisition of Clinpal and Winterlight (24 months ago) and subsequent product development, Cambridge Cognition could have only provide the secondary endpoint for this trial. It is interesting and significant that Cambridge Cognition replaced Cogstate, which had provided the non-eCOA work in earlier trials. Normally, I would not pay too much attention to this; however, in Alzheimer's Disease (AD), Cogstate is the dominant player and has digital offerings so this is significant. This hints at a significant increase in the potential opportunity set in other trials/indications where rater based scales are used as primary endpoints and AQUA is relevant such as PANNS, ADAS-COG, HAM-A, HAM-D etc and where a CANTAB battery may only be an exploratory or secondary endpoint. |
Posted at 09/1/2025 07:22 by jasperlachat The share price remains some way adrift of when Stork got the boot. Everything looking pretty positive since, if not quite exciting. Cog looks better set than ever imo. Benchmark that with the trading heights of £1.50+ in 2022. |
Posted at 08/1/2025 14:54 by tom111 News report by Share cast can be found on Lse board under News Headlines "COG product used in Schizophrenia trial" hence imo the rise to day. |
Posted at 11/12/2024 03:24 by 40 fathoms Having read the updates from Dowgate and PL. One key point I noted is that both have forecasted a lower revenue number than management's forecast @12.5 mn and 12.6 mn respectively. PL's note states that management is targeting a 30% to 40% increase in revenue for FY25 over FY24, but PL has chosen to take a more conservative approach.If COG achieves the top end of management's target (40%), it would align closely with the previous FY25 revenue forecast PL had at the interims. To me this suggests a general shift in revenue expectations to the right, rather than a change in the shape of the overall revenue outlook. The cash draw in the second half versus a breakeven adjusted EBITDA is a bit harder to figure out. £600k will go towards the monthly repayments of the Claret Loan, and £137.5k will cover interest on that loan. This leaves approximately £1.6 million. There might be some restructuring costs related to the CEO and CFO departures, but the significant balance is likely working capital. This is probably accounted for by the difference between invoicing (and thus revenue recognition on new contracts won late in the year) and cash collection. If correct, this will convert back to cash early in FY25 and may explain the confident tone in the RNS; this situation will further improve with additional contract wins. |
Posted at 10/12/2024 14:17 by earwacks COG gets a mention by a certain commentator as a company worth looking at.’worried about its ability to scale up.’ I would not have thought that as an issue, more about its ability to confirm orders. Anyone know what the margins are for Cog ? Usually pretty good for unique specialist software |
Posted at 28/11/2024 12:12 by jasperlachat Anyone know what Stork is up to, other than having a ghostly presence on the Cog sp? |
Posted at 07/11/2024 15:51 by earwacks The only good thing I like about Cog is the relatively low share count. At the present time there are too many things up in the air. The big caveat for Monument is the ‘if successful’ valuation attributed to Cog. Dowgate dont appear to have any further insight to senior management upheaval,other than to say it has stabilised.( PT still £1.25. ) Well of course it has for now after devaluing the company by 40%! The market is brilliant at reacting like this. I dont know why companies cant add a little comment to try and mitigate the usual over reaction. Its an opportunity maybe, but a blind one and not right after a placing thanks very much. Poor all round. Zero point. |
Posted at 07/11/2024 12:01 by jasperlachat RNS highlights c£1.8m increase in balance sheet, yet Cog M/Cap remains at a paltry £12m. Impossible to remain independent imo. Someone’s going to gobble us up. With the assurance that all is good despite the departure of Stork, someone must be running the slide rule over this. I would if I had more funds! |
Posted at 05/9/2024 12:33 by 40 fathoms This was posted today, no RNS but interesting nonetheless.Don't seem able to post the link, so here is a copy of the text "US patient recruitment firm Splash Clinical has teamed up with UK-based digital brain health services provider Cambridge Cognition (COG) to help sponsors find people to participate in central nervous system (CNS)-focused drug trials. The new partnership – financial terms of which were not disclosed – will see Splash utilize COG’s pre-screening technology to assess potential participants for studies focusing on CNS indications. In a press statement, Splash CEO Matt Teuteberg, said, “By integrating their assessment tools into our platform, we will increase our efficiency in finding the right patients for clinical trials. This partnership will save time and resources for our clients and ultimately make treatments available for patients faster.” CNS recruitment Finding the right patients to take part in drug research is always difficult, nonetheless of the disease involved. Recruiting for trials focusing on neurological disorders is a particular challenge. For example, a 2023 study in the journal Innovations in Clinical Neuroscience suggested the lack of information about CNS patients combined with the nature of the diseases themselves are the issue. “In contrast to other therapeutic areas, such as oncology or cardiovascular diseases, there are no large clinical research networks for CNS, making it more difficult to efficiently reach patients in their care setting. There are also challenges associated with CNS disorders themselves that are not relevant to other therapeutic areas … Thus, the timely recruitment and retention of the right and representative patients is a challenge for CNS clinical trials.” COG’s technology is designed to address such difficulties. The system consists of an online cognitive assessment portal that gathers and processes data from potential study participants. According to the firm, the assessment, which takes around ten minutes, reduces screening failures and increases the quality of patients entering the trial. Splash said that, in combination with its own suite or recruitment tools, the new tech will help it reach a broader population while maintaining high-quality standards. Liam Kaufman, Cambridge Cognition’s vice president of clinical sciences, emphasized the potential benefits of the collaboration, explaining “They’ve got a great recruitment platform and a solid track record in recruitment. Our tools complement their process perfectly. Our goal is to make it easier for researchers to find the right participants for their CNS trials. It’s a win-win for everyone involved.” She added that during a pilot collaboration completed last year, COG’s software helped filter in hard-to-find patients with early Alzheimer’s symptoms. News of the collaboration comes a few months after the Michael J. Fox Foundation began using COG’s technology to identify the cognitive profile of Parkinson’s Disease patients as part of an effort to identify biomarkers – and potential druggable targets – for the condition. |
Posted at 25/6/2024 00:04 by 40 fathoms @bedford1976 - They are already international in their reach and the significant percentage of their revenue is generated outside of the UK. This is mainly done directly and not via partnership. That said they do have an exclusive partnership for the China market and they have talked in the past about the possibility of non exclusive partnerships with CROs and certain Pharma. This aside I think most likely partnerships are likely to be technology based rather than geographical. The recent ActiGraph partnership being a good example. The other areas they have suggested they would look to partnership is for the healthcare and diagnostics opportunity.@Yump - For the potential size and scope of larger contracts you can look at Cogstate listed in Australia. They have a contracted order book in excess of US$100 million and in the last 3 or 4 years they have signed 1 contract in excess of US$10 million and one in excess of US$ 25 million. The larger one was for Eli Lilly and they worked on the Donanamab Phase III trial, which are currently with the FDA for approval. Both of these contracts were for providing work in to Phase III AD trials (AD is Cogstate's core area. About half of these amounts is accounted for by the provision of raters and rater training, which COG does not provide, so these numbers would need to be cut by 50% to get a sense of what a very large contract for COG might look like. In the next 24/36 months it is a certainty that we will see numerous contracts in excess of GBP 3 million and maybe one or two that tops GBP 5 million. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
